Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.

[1]  R. Elstrom,et al.  Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration , 2014, Haematologica.

[2]  T. Ortel,et al.  14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. , 2014, Autoimmunity reviews.

[3]  F. Carrat,et al.  Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey. , 2014, Autoimmunity reviews.

[4]  P. Bierling,et al.  Safety and Efficacy Of Rituximab In adult’s Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry , 2013 .

[5]  F. Roudot-thoraval,et al.  Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia , 2013, American journal of hematology.

[6]  Y. Shoenfeld,et al.  Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. , 2013, Autoimmunity reviews.

[7]  D. Roccatello,et al.  Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. , 2013, Autoimmunity reviews.

[8]  G. Ruiz-Argüelles,et al.  High response rate to low‐dose rituximab plus high‐dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia , 2013, European journal of haematology.

[9]  D. Sène,et al.  Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. , 2013, Autoimmunity reviews.

[10]  L. Kjeldsen,et al.  Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. , 2013, Blood.

[11]  D. Furst,et al.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients , 2012, Annals of the rheumatic diseases.

[12]  M. Šimkovič,et al.  Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice , 2012, International Journal of Hematology.

[13]  R. Fanin,et al.  Long‐term follow‐up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia , 2012, American journal of hematology.

[14]  D. Isenberg.  Rituximab-it was the best of times, it was the worst of times. , 2012, Autoimmunity reviews.

[15]  J. Bussel,et al.  How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. , 2012, Blood.

[16]  E. Peeva,et al.  B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data. , 2012, Autoimmunity reviews.

[17]  J. Rossi,et al.  Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta‐analysis , 2012, British journal of haematology.

[18]  J. Stone,et al.  B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. , 2012, Autoimmunity reviews.

[19]  E. Neufeld,et al.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. , 2012, Blood.

[20]  R. Vollenhoven,et al.  Rituximab - shadow, illusion or light? , 2012 .

[21]  D. Isenberg,et al.  Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. , 2012, Autoimmunity reviews.

[22]  D. Cook,et al.  A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. , 2012, Blood.

[23]  C. Cunningham-Rundles,et al.  Efficacy and safety of rituximab in common variable immunodeficiency‐associated immune cytopenias: a retrospective multicentre study on 33 patients , 2011, British journal of haematology.

[24]  M. Werner,et al.  T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. , 2011, Blood.

[25]  M. Sanz,et al.  Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[26]  R. Fanin,et al.  Low‐dose rituximab in adult patients with primary immune thrombocytopenia , 2010, European journal of haematology.

[27]  R. Fanin,et al.  Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. , 2010, Blood.

[28]  D. Arnold,et al.  The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases , 2010, British journal of haematology.

[29]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[30]  C. Thornburg,et al.  PERSISTENT ANTIBODY DEPLETION AFTER RITUXIMAB IN THREE CHILDREN WITH AUTOIMMUNE CYTOPENIAS , 2009, Pediatric hematology and oncology.

[31]  J. Leonard,et al.  Repeated courses of rituximab in chronic ITP: Three different regimens , 2009, American journal of hematology.

[32]  M. Blinder,et al.  Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: A report of 13 cases and review of the literature , 2009, American journal of hematology.

[33]  A. Thrasher,et al.  Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin , 2009, British journal of haematology.

[34]  O. Ayyıldız,et al.  The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura , 2009, Journal of Thrombosis and Thrombolysis.

[35]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[36]  S. Mousa,et al.  Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) , 2009, Annals of Hematology.

[37]  R. Calabrese,et al.  Long‐term follow‐up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response , 2009, British journal of haematology.

[38]  R. Fanin,et al.  Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long‐term follow‐up results , 2008, European journal of haematology.

[39]  R. Porcher,et al.  Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. , 2008, Blood.

[40]  Lennart Hammarstrom,et al.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes. , 2008, Blood.

[41]  R. Fanin,et al.  Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura , 2008, Haematologica.

[42]  É. Oksenhendler,et al.  Infections in 252 patients with common variable immunodeficiency. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  A. Majluf-Cruz,et al.  Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis , 2007, Annals of Hematology.

[44]  A. Ho,et al.  Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab , 2007, Annals of Hematology.

[45]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[46]  M. Leandro,et al.  B cell depletion therapy in rheumatic disease. , 2006, Best practice & research. Clinical rheumatology.

[47]  S. Perrotta,et al.  Rituximab (anti-cd20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment , 2006, International journal of hematology.

[48]  M. Loh,et al.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. , 2006, Blood.

[49]  F. Peñalver,et al.  Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients , 2006, Annals of Hematology.

[50]  T. Plesner,et al.  Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura , 2005, American journal of hematology.

[51]  J. Bussel,et al.  Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. , 2005, The Journal of pediatrics.

[52]  É. Oksenhendler,et al.  Autoimmune Thrombocytopenic Purpura and Common Variable Immunodeficiency: Analysis of 21 Cases and Review of the Literature , 2004, Medicine.

[53]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[54]  J. Penner,et al.  Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab) , 2003, American journal of hematology.

[55]  A. Fischer,et al.  Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  U. Germing,et al.  Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study , 2002, European journal of haematology.

[57]  S. Amadori,et al.  Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.

[58]  C. Cunningham-Rundles,et al.  Hematologic complications of primary immune deficiencies. , 2002, Blood reviews.

[59]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[60]  C. Cunningham-Rundles,et al.  Common variable immunodeficiency: clinical and immunological features of 248 patients. , 1999, Clinical immunology.

[61]  C. Cunningham-Rundles,et al.  New Insights into Common Variable Immunodeficiency , 1993, Annals of Internal Medicine.

[62]  Kailin Xu,et al.  Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia , 2011, International journal of hematology.

[63]  Eren,et al.  The EUROclass trial: defining subgroups in common variable immunodeficiency. , 2008, Blood.

[64]  R. Fanin,et al.  B-cell compartment as the selective target for the treatment of immune thrombocytopenias. , 2003, Haematologica.